175 related articles for article (PubMed ID: 34267237)
21. RADIATION PROTECTION IN THE RELEASE OF PATIENTS RECEIVING 131I TREATMENT.
Mattar E; Salih MA; Alsafi K; Suliman II
Radiat Prot Dosimetry; 2019 Dec; 187(4):499-508. PubMed ID: 31605121
[TBL] [Abstract][Full Text] [Related]
22. Radiation doses to cohabitants of patients undergoing radioiodine ablation for thyroid cancer: poor compliance with radiation protection guidelines but low radiation exposure.
Gabriel S; Farman-Ara B; Bourrelly M; Carpentier O; Sebag F; Palazzo FF; De Micco C; Mancini J; Henry JF; Mundler O; Taïeb D
Nucl Med Commun; 2011 Sep; 32(9):829-33. PubMed ID: 21633315
[TBL] [Abstract][Full Text] [Related]
23. Potential third-party radiation exposure from outpatients treated with 131I for hyperthyroidism.
Matheoud R; Reschini E; Canzi C; Voltini F; Gerundini P
Med Phys; 2004 Dec; 31(12):3194-200. PubMed ID: 15651602
[TBL] [Abstract][Full Text] [Related]
24. Protection problems in radionuclide therapy: the patient as a gamma-radiation source.
Pochin EE; Kermode JC
Br J Radiol; 1975 Apr; 48(568):299-305. PubMed ID: 1131488
[TBL] [Abstract][Full Text] [Related]
25. Thyroid remnant ablation using 1,110 MBq of I-131 after total thyroidectomy: regulatory considerations on release of patients after unsealed radioiodine therapy.
Kusakabe K; Yokoyama K; Ito K; Shibuya H; Kinuya S; Ito M; Higashi T; Togawa T; Koizumi K; Yoshimura M; Uchiyama M; Okamoto T; Kanaya S; Kanaya K; Yoneyama T; Ikebuchi H; Yanagida S; Shibata K; Segawa K; Yamamoto A
Ann Nucl Med; 2012 May; 26(4):370-8. PubMed ID: 22450825
[TBL] [Abstract][Full Text] [Related]
26. A comprehensive dose reconstruction methodology for former rocketdyne/atomics international radiation workers.
Boice JD; Leggett RW; Ellis ED; Wallace PW; Mumma M; Cohen SS; Brill AB; Chadda B; Boecker BB; Yoder RC; Eckerman KF
Health Phys; 2006 May; 90(5):409-30. PubMed ID: 16607174
[TBL] [Abstract][Full Text] [Related]
27. Occupational and patients effective radiation doses in dental imaging.
Tamam N; Almuqrin AH; Mansour S; Elnour A; Musa M; Omer H; Sulieman A; Bradley DA
Appl Radiat Isot; 2021 Nov; 177():109899. PubMed ID: 34438276
[TBL] [Abstract][Full Text] [Related]
28. Dose to fingertips of staff preparing stranded iodine-125 seeds for permanent prostate implants.
van Haaren PM; van't Riet A; Moerland MA; Koedooder C; Westendorp H
Radiat Prot Dosimetry; 2011 Apr; 145(1):61-5. PubMed ID: 21112885
[TBL] [Abstract][Full Text] [Related]
29. [Changes in radioiodine therapy for thyroid disorders].
Konrády A
Orv Hetil; 2016 Jan; 157(3):83-8. PubMed ID: 26750728
[TBL] [Abstract][Full Text] [Related]
30. Radioiodine treated hyperthyroidism and thyroid carcinoma.
Appell R; Tsangaris N; Spiegel J
Am Surg; 1978 Aug; 44(8):537-40. PubMed ID: 707910
[TBL] [Abstract][Full Text] [Related]
31. [Radioiodine 131I therapy of hyperthyroidism on an outpatient basis - safe, effective and economic option].
Jiskra J; Kubinyi J; Telička Z
Vnitr Lek; 2012 Feb; 58(2):94-8. PubMed ID: 22463087
[TBL] [Abstract][Full Text] [Related]
32. Radiation dose to the testes after 131I therapy for ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer.
Ceccarelli C; Battisti P; Gasperi M; Fantuzzi E; Pacini F; Gualdrini G; Pierantoni MC; Luciani A; Djokich D; Pinchera A
J Nucl Med; 1999 Oct; 40(10):1716-21. PubMed ID: 10520714
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of patient and staff doses during various CT fluoroscopy guided interventions.
Buls N; Pagés J; de Mey J; Osteaux M
Health Phys; 2003 Aug; 85(2):165-73. PubMed ID: 12938963
[TBL] [Abstract][Full Text] [Related]
34. [Problems with radiation protection for adjuvant radiotherapy of thyroid cancer].
Siekierzyński M
Wiad Lek; 2001; 54 Suppl 1():307-11. PubMed ID: 12182040
[TBL] [Abstract][Full Text] [Related]
35. Dosimetry and risk estimates of radioiodine therapy for large, multinodular goiters.
Huysmans DA; Buijs WC; van de Ven MT; van den Broek WJ; Kloppenborg PW; Hermus AR; Corstens FH
J Nucl Med; 1996 Dec; 37(12):2072-9. PubMed ID: 8970537
[TBL] [Abstract][Full Text] [Related]
36. Cytogenetic damage after 131-iodine treatment for hyperthyroidism and thyroid cancer. A study using the micronucleus test.
Gutiérrez S; Carbonell E; Galofré P; Creus A; Marcos R
Eur J Nucl Med; 1999 Dec; 26(12):1589-96. PubMed ID: 10638411
[TBL] [Abstract][Full Text] [Related]
37. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I : practice recommendations of the American Thyroid Association.
; Sisson JC; Freitas J; McDougall IR; Dauer LT; Hurley JR; Brierley JD; Edinboro CH; Rosenthal D; Thomas MJ; Wexler JA; Asamoah E; Avram AM; Milas M; Greenlee C
Thyroid; 2011 Apr; 21(4):335-46. PubMed ID: 21417738
[TBL] [Abstract][Full Text] [Related]
38. Thyroid cancer patients treated with 131I: radiation dose to relatives after discharge from the hospital.
Rémy H; Coulot J; Borget I; Ricard M; Guilabert N; Lavielle F; Camps E; Baudin E; Lumbroso J; Leboulleux S; Schlumberger M
Thyroid; 2012 Jan; 22(1):59-63. PubMed ID: 22136157
[TBL] [Abstract][Full Text] [Related]
39. Dose to Medical Personnel.
Misdaq MA; Harrass H; Saikouk H; Matrane A
Health Phys; 2020 Feb; 118(2):129-135. PubMed ID: 31658162
[TBL] [Abstract][Full Text] [Related]
40. Staff eye doses in a large medical centre in Saudi Arabia: are they meeting the new ICRP recommendations?
Al-Haj AN; Lobriguito AM; Al-Gain I
Radiat Prot Dosimetry; 2015 Jul; 165(1-4):294-8. PubMed ID: 25848104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
